Bai et al. reported that SNHG17 promoted the progression of castration-resistant prostate cancer via the miR-144/CD51 axis, indicating that SNHG17 may serve as a therapeutic target in prostate cancer [36]. This evidence concerns the gene SNHG17 and prostate cancer.